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Summary Hemokinin-1 (HK-1) and endokinins are peptides predicted from a new mammalian
tachykinin gene, TAC4. The amino acid sequences derived from rat/mouse HK-1 and human HK-1
are not identical; however, the effects induced by intracerebroventricular or intrathecal
administration of HK-1 are attenuated by treatment with antagonists of neurokinin 1 (NK1)
receptor, substance P (SP) receptor, indicating that HK-1 is an agonist of the NK1 receptor. On the
other hand, a growing body of evidence indicates that pharmacological characteristics of HK-1
and SP are always not identical, suggesting that the HK-1-preferred receptor may be involved in
the effects of HK-1. Endokinins are derived from human TAC4 and consist of four endokinins,
endokinin A (EKA), endokinin B (EKB), endokinin C (EKC) and endokinin D (EKD). Effects induced by
intrathecal administration of EKA/B (the common C-terminal decapeptide in EKA and EKB) and SP
were very similar, while the effects of SP and EKA/B were inhibited by EKC/D (the common C-
terminal duodecapeptide in EKC and EKD). This inhibitory effect of EKC/D was derived from
leucine at the carboxyl-terminus. These findings suggest that HK-1 and EKA/B have an agonistic
effect, while EKC/D has an antagonistic effect on the NK1 receptor in nociceptive processing.
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28 T. Nishimori et al.1. Classical concept of mammalian
tachykinin peptide
In 1931, von Euler and Gaddum purified the first substance
designated as preparation P or powder P from the brain and
intestine of rabbits and found that it had an effect on blood
pressure and contraction of intestinal tissue [1]. The pure
form of this substance, substance P (SP), was not isolated for
the next 40 years. A peptide named sialogen was isolated in
1967 from the bovine and rat hypothalamus [2]. In 1970, by
comparing their biological activity and chemical properties,
it was realized that sialogen and SP are the same [3]. There-
after, the chemical structure of SP was determined as an
amidated undecapeptide [4] and SP was chemically synthe-
sized (Table 1) [5]. Over the next 10 years, SP was believed to
be the only mammalian tachykinin peptide. In 1983, two
further members of the mammalian tachykinin family were
isolated from the porcine spinal cord and were designated as
neurokinin A (NKA, substance K, neuromedin L) (Table 1) [6,7]
and neurokinin B (NKB, neuromedin K) (Table 1) [8,9]. On the
other hand, based on a cloning study for the precursor of
mammalian tachykinin, it was verified that the preprotachy-
kinin A (PPT-A, TAC1) [10,11] encodes SP and NKA, while NKB
is encoded in preprotachykinin B (PPT-B, TAC3) [12]. In 1989,
receptors of each of these three mammalian tachykininsTable 1 Amino acid sequence of the different groups of mamma
Tachykinin 
Neurokinins
SP 
[Leu11]-SP 
HK-1 (1—5)/SP 
NKA 
NKB 
Hemokinins
r/mHK-1 
SP (1—5)/HK-1 
hHK-1 
Endokinins
EKA 
EKB 
EKA/B 
[Leu10]-EKA/B 
EKC 
EKD 
EKC/D 
[Met12]-EKC/D 
[D-Trp8]-EKC/D 
[D-Trp10]-EKC/D 
[D-Trp8,10]-EKC/D were cloned and designated as neurokinin 1 (NK1), neuroki-
nin 2 (NK2) and neurokinin 3 (NK3) receptors [13—19]. Thus,
until recently, it had been believed that mammalian tachy-
kinin peptides consist of three members, SP, NKA and NKB,
which are short peptides 10—11 amino acids in length.
Furthermore, these peptides share the same conserved
hydrophobic carboxyl-terminal (C-terminal) region, Phe—
X—Gly—Leu—Met—NH2, which is central to the activation
of each of three mammalian tachykinin receptors. In con-
trast, in the amino-terminal (N-terminal) region, they pos-
sess divergent and hydrophilic regions believed to convey
receptor specificity, whereby SP shows the highest affinity for
NK1, NKA for NK2 and NKB for NK3 receptor [17—19]. Namely,
it seems likely that NK1, NK2 and NK3 receptors are receptors
of SP, NKA and NKB, respectively. In 2000, this consensus had
to be changed after the discovery of a fourth mammalian
tachykinin in mice [20].
2. Structure and distribution of hemokinin-1
2.1. Identification of PPT-C (TAC4) in mammals
A new cDNA molecule was identified from an mRNA differ-
ential display for isolating new growth and differentiation
factors involved in mouse B cell development [20]. Thelian tachykinins and related peptides.
Amino acid sequence
RPKPQQFFGLM-NH2
RPKPQQFFGLL-NH2
RSRTRQFFGLM-NH2
HKTDSFVGLM-NH2
DMHDFFVGLM-NH2
RSRTRQFYGLM-NH2
RPKPQQFYGLM-NH2
TGKASQFFGLM-NH2
DGGEEQTLSTEAETWVIVALEEGAGPSIQLQLQEVK-
TGKASQFFGLM-NH2
DGGEEQTLSTEAETW————————EGAGPSIQLQLQEVK-
GKASQFFGLM-NH2
KASQFFGLM-NH2
KASQFFGLL-NH2
KAYQLEHTFQGLL-NH2
GAYQLEHTFQGLL-NH2
YQLEHTFQGLL-NH2
YQLEHTFQGLM-NH2
YQLEHT-[D-Trp]-QGLM-NH2
YQLEHTFQ-[D-Trp]-LM-NH2
YQLEHT-[D-Trp]-Q-[D-Trp]-LM-NH2
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of 128 amino acids with a 15 amino acid region, Lys—Arg—
Ser—Arg—Thr—Arg—Gln—Phe—Tyr—Gly—Leu—Met—Gly—Lys—
Arg, that is similar to tachykinin peptides, since this region
possesses all the sequence information necessary for the
liberation and maturation of a tachykinin peptide. Specifi-
cally, the basic Lys—Arg doublets at each end are typical
cleavage sites, and the Gly residue adjacent to the COOH-
terminal Met residue provides the NH2 group for COOH-
terminal amidation of the mature tachykinin peptide. The
pentapeptide sequence Phe—Tyr—Gly—Leu—Met matches the
tachykinin signature motif Phe—X—Gly—Leu—Met. Thus, it
was suggested that the cDNA molecule is a new mouse
preprotachykinin gene, mPPT-C (mTAC4), and the putative
tachykinin peptide encoded by mTAC4 was named hemokinin-
1 (HK-1), because this gene was restrictedly expressed in
hematopoietic cells, and the structure of HK-1 was proposed
as Arg—Ser—Arg—Thr—Arg—Gln—Phe—Tyr—Gly—Leu—Met—
NH2 (Table 1) [20]. Subsequently, the rat TAC4 encoding a
precursor protein of 170 amino acids was identified. This
precursor protein encoding a rat HK-1 peptide (rHK-1) dis-
played 76% identity to that of the mouse (mHK-1) and the
amino acid sequence of rHK-1 was identical to that of mHK-1,
so it was named rat/mouse hemokinin (r/mHK-1) [21]. Simi-
larly, cDNA encoding a precursor protein of 98 amino acids
was identified from human hypothalamic and thymus DNA
and was designated human preprotachykinin C (hPPT-C,
hTAC4)) [21]. The putative peptide encoded by hTAC4 was
also homologous to that of mTAC4; however, unlike the
mTAC4 gene in which dibasic cleavage sites flank the pre-
dicted HK-1 peptide, the putative peptide encoded by hTAC4
contained two potential monobasic cleavage sites (Lys) in the
N-terminal region, Lys—Thr—Gly—Lys—Ala—Ser—Gln—Phe—
Phe—Gly—Leu—Met—Gly—Lys—Arg. As a result, the putative
peptide of human HK-1 (hHK-1) has the potential to generate
the full-length Thr—Gly—Lys—Ala—Ser—Gln—Phe—Phe—Gly—
Leu—Met—NH2 (Table 1), as well as a truncated version, Ala—
Ser—Gln—Phe—Phe—Gly—Leu—Met—NH2, of predicted human
HK-1 [21].
2.2. Tissue distribution of TAC4
The mTAC4 gene was restrictedly expressed in bone marrow,
while there was little expression of TAC4 mRNA in the mouse
brain and spleen [20]. Detailed examination of the expres-
sion pattern of mTAC4 and hTAC4 revealed the differential
expression of these mRNAs in various tissues. For example,
moderate to strong signals of mTAC4 were detected in the
brain, spleen, stomach, and skin, while stronger expression
of hTAC4 was seen in the heart, muscle, skin, and thyroid.
Thus, TAC4 appears to be expressed in certain peripheral
tissues and in the brain of both humans and rodents [21]. By
contrast, comparison of mTAC4 and mTAC1 expression
showed tissue-dependent differences. Indeed, the expres-
sion of mTAC4 was found in the majority of peripheral
tissues, while mTAC1 had more limited distribution in the
central nervous system (CNS). These findings suggest that
HK-1 may be a functional agonist at NK1R in the CNS as well as
in peripheral tissues [22], and strong expression of TAC4
in the skin suggests that HK-1 may play a crucial role in
inflammation or somatosensory perception, such as touch,
pain or itch.It is known that the expression level of TAC1 is modified in
pathophysiological conditions such as nerve injury; however,
there was a little information about changes in the expression
level of TAC4. Recently, the increased level of TAC4 mRNA
was demonstrated in the dorsal horn after chronic constric-
tive injury (CCI) of the rat sciatic nerve, and the increased
expression of TAC4 mRNA after CCI was blocked by treatment
with an inhibitor of microglial activation. This indicates that
the increased expression of TAC4 mRNA is involved, at least in
part, in the activation of microglial cells after nerve injury
[23]. Furthermore, the expression of TAC4 mRNA was upre-
gulated in the microglia upon their activation by lipopoly-
saccharide, whereas TAC1 mRNA expression was
downregulated, suggesting that HK-1, rather than SP, plays
crucial roles in pathological conditions associated with
microglial activation [24].
2.3. Pharmacological characteristics of HK-1
The high degree of homology between amino acid sequences
of SP and r/mHK-1 suggests that r/mHK-1 peptide may
interact with the SP-preferred receptor, NK1 receptor. Com-
petition binding experiments of r/mHK-1 in cells transfected
with NK1 receptor showed identical binding affinity to that of
SP, and calcium influx in cells expressing NK1 receptor fol-
lowing r/mHK-1 administration was equipotent to SP, sug-
gesting that r/mHK-1 may be a full agonist at NK1 receptor
[25]. Subsequent study demonstrated that r/mHK-1 and SP
bound to the human NK1 receptor with similar affinity, while
r/mHK-1 had reduced affinity for the human NK2 receptor
and NK3 receptor relative to the NK1 receptor [21,22]. In
addition, calcium mobilization by hHK-1 and r/mHK-1
showed potency equal to SP on the human NK1 receptor
expressed in CHO cells [21], and SP and r/mHK-1 displayed
higher affinity at the human NK1 receptor expressed in CHO
cells [22,26]. Similarly, the effect of bath application of SP
and r/mHK-1 on the rabbit jugular vein expressing NK1
receptor was examined, and similar kinetics of action of
SP and HK-1 was demonstrated [27]. These results indicate
that r/mHK-1 is an agonist at NK1 receptor, and both SP and r/
mHK-1 competitively bind to the NK1 receptor; however,
these data could not always rule out the possible existence
of an HK-1-preferring receptor [20,28].
3. Pharmacological effects of HK-1
Since the discovery of r/mHK-1, many studies have focused
on its biological actions, including immunological regulation
and inflammation [20,29—33], female reproductive function
[34—37] and cardiovascular activities [26,38—40]. As space is
limited for a full explanation of these fields and data from the
pain field are relatively abundant, the main subject of this
review will be the biological role of HK-1 in nociceptive
processing.
3.1. Effects of intracerebroventricular
administration of HK-1
First, it was demonstrated that injection of r/mHK-1 and SP
into the third ventricle produced a dose-dependently
increase in foot-tapping in gerbils and scratching in mice
30 T. Nishimori et al.and these HK-1-induced behaviors were blocked by a selec-
tive NK1 receptor antagonist [22], indicating that r/mHK-1 is
involved in the induction of these behavioral responses
through the NK1 receptor. Subsequently, to observe the
effects of r/mHK-1 on nociceptive processing at the suprasp-
inal level in mice, different concentrations of r/m HK-1 were
administered into the third ventricle and the effect of r/
mHK-1 was evaluated by the warm-water tail-immersion
test. Intracerebroventricular (i.c.v.) administration of r/m
HK-1 induced the analgesic effect in nanomole concentra-
tion, while picomolar doses produced hyperalgesia. These
effects were attenuated by co-injection with a selective NK1
receptor antagonist, suggesting that r/mHK-1 may play a
crucial role in nociceptive processing at the supraspinal level
in mice and both conflicting effects of r/mHK-1 may be
elicited through the activation of NK1 receptor [41]. Further-
more, the antinociceptive effect induced by r/mHK-1 admin-
istration was attenuated by pretreatment with naloxone, an
opioid receptor antagonist [41], indicating that there is a
functional interaction between supraspinal HK-1 and opioid
systems. Indeed, i.c.v. administration of r/mHK-1 signifi-
cantly potentiated the antinociceptive effects of morphine
or pethidine, an opioid receptor agonist, indicating that the
potential analgesic response induced by i.c.v. administration
of r/m HK-1 is mediated by opioid-responsive neurons
[42,43]. On the other hand, the effects of hHK-1 and hHK-
1 (4—11) were investigated by the tail immersion test follow-
ing i.c.v. administration at the supraspinal level in mice. The
antinociceptive effect produced by i.c.v. administration of
hHK-1 was significantly antagonized by an NK1 receptor
antagonist, indicating that the analgesic effect induced by
i.c.v. administration of hHK-1 is mediated through the acti-
vation of NK1 receptor. Similarly, naloxone blocked the
analgesic effect of hHK-1, suggesting that this effect is
related to opioidergic neurons. On the other hand, i.c.v.
administration of hHK-1 (4—11) also produced an antinoci-
ceptive effect; however, this effect was not attenuated by
administration of an NK1 receptor antagonist or naloxone,
suggesting that the mechanisms underlying the antinocicep-
tive effect induced by hHK-1 and hHK-1 (4—11) may be
different [44].
In summary, it seems likely that i.c.v. administration of
HK-1 elicits antinociceptive effects through the NK1 receptor
and this effect is derived from activation of the opioid
system.
3.2. Effects of intrathecal administration of HK-1
It is well known that intrathecal administration of SP induces
scratching behavior and thermal hyperalgesia [45,46].
Scratching behavior was also induced by intrathecal admin-
istration of r/mHK-1 [47,48], and HK-1-induced scratching
behavior was attenuated by pretreatment with an NK1 recep-
tor antagonist [47], whereas SP-induced scratching behavior
was inhibited by pretreatment with EKC/D (using the com-
mon carboxyl-terminal duodecapeptide in endokinin C and
endokinin D), but failed to attenuate HK-1-induced scratch-
ing behavior [49]. Similarly, intrathecal administration of r/
mHK-1 produced scratching, biting and licking behaviors.
These behaviors induced by low-dose HK-1 were inhibited
by CP-99,994, a non-peptidic NK1 receptor antagonist,
whereas sendide, a peptidic NK1 receptor antagonist, failedto reduce the behavior responses, although SP-induced beha-
viors were suppressed by both CP-99,994 and sendide [50].
These findings indicate that the mechanism underlying the
induction of behaviors by r/mHK-1 is partially different from
that of SP.
Repeated intrathecal administration of SP produced
desensitization in SP-induced behavior such as scratching,
biting and thermal hyperalgesia [51—54]. Similarly induction
of desensitization in scratching behavior was also recognized
after repeated administration of r/mHK-1 [48,49,55].
Indeed, marked desensitization of scratching behavior was
recognized when r/mHK-1 was administered twice. Further-
more, the first administration of SP produced clear cross-
desensitization to r/mHK-1, while the first administration of
r/mHK-1 demonstrated weak cross-desensitization to SP
[48]. Induction of desensitization by repeated administration
of r/mHK-1 was attenuated by pretreatment with an inhi-
bitor of protein kinase A (PKA), protein kinase C (PKC) or
mitogen-activated protein kinase (MEK), while there was
little effect of an inhibitor of calcium/calmodulin kinase II
(CaMKII) on r/mHK-1-induced desensitization, although pre-
treatment with these four kinase inhibitors inhibited the
induction of desensitization by SP [55]. Since it is believed
that desensitization is induced by binding of peptide to its
receptor, the difference in the mode of induction of cross-
desensitization between r/mHK-1 and SP and in kinases
involved in the induction of desensitization suggests that
the receptor of r/mHK-1, HK-1-preferring receptor, may be
different from the SP-preferring receptor, NK1 receptor.
Another notable difference between the effects of r/
mHK-1 and SP is the scarcely induced thermal hyperalgesia
by intrathecal administration of r/mHK-1, but not SP [47].
This issue has been partially resolved by synthesizing chimera
peptides between r/mHK-1 and SP. When two chimera pep-
tides between the N-terminal region of SP and the C-terminal
region of r/mHK-1, and vice versa, SP (1—5)/HK-1 and HK (1—
5)/SP (Table 1), were intrathecally administered, SP (1—5)/
HK-1 induced thermal hyperalgesia whereas HK-1 (1—5)/SP
had hardly any effect; furthermore, thermal hyperalgesia
was induced by only C-terminal fragments of r/mHK-1 and SP,
indicating that the N-terminal region of r/mHK-1 is involved
in the non-induction of thermal hyperalgesia. Both SP (1—2)/
HK-1 and HK-1 (1—4)/SP induced thermal hyperalgesia
whereas r/mHK-1 and HK-1 (1—5)/SP had hardly any effect,
indicating that Ser at the 2nd position and Arg at the 5th
position of r/mHK-1 may be involved in the non-induction of
thermal hyperalgesia. Furthermore, HK-1 (1—2, 4—5)/SP, but
not HK-1 (1—2,5)/SP and HK-1 (1—3,5)/SP, hardly induced
thermal hyperalgesia, indicating that three amino acids, Ser,
Thr and Arg at the 2nd, 4th and 5th position of r/mHK-1,
respectively, regulate the induction of thermal hyperalgesia
by r/mHK-1 [56].
There is a functional relationship between r/mHK-1 and
ion channels. Three transient receptor potential (TRP) chan-
nels, TRPV1, TRPA1 and TRPM8, and r/mHK-1, are similarly
localized in the spinal dorsal horn and dorsal root ganglion
[22,57—65]. Thus, the effects of pretreatment with HK-1 on
the induction of scratching behavior by TRP channel agonists
were examined. Pretreatment with HK-1 enhanced the
induction of scratching behavior by resiniferatoxin, a TRPV1
agonist, whereas scratching behavior induced by menthol, a
TRPM8 agonist, was suppressed by pretreatment with HK-1.
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with HK-1 on the induction of scratching behavior by cinna-
maldehyde, a TRPA1 agonist. Taken together, these results
indicate that HK-1 differentially modulates the response of
TRP channels [66].
4. Structure and distribution of endokinins
4.1. Structure of hTAC4
A corresponding human TAC4 homologue to mouse and rat
TAC4 was isolated and an HK-1-like decapeptide, Gly—Lys—
Ala—Ser—Gln—Phe—Phe—Gly—Leu—Met—NH2, with the
tachykinin signature motif was predicted to be encoded on
this precursor [21,67]. This peptide does not share complete
homology with mouse or rat HK-1. The human TAC4 proposed
by Kurtz et al. [21] is encoded only on two exons equivalent to
the first two coding exons of mice and rats. On the other
hand, Page et al. [67] identified cDNA from the human spleen
that rendered a much longer 113-amino acid precursor pro-
tein predicted to be encoded on five exons, indicating that
there are three additional downstream exons in humans.
Furthermore, this human TAC4 is spliced into four alterna-
tively splice variants, a, b, g and d and four different
peptides are predicted, classified as endokinin A (EKA),
endokinin B (EKA), endokinin C (EKC) and endokinin D
(EKD) (Table 1). EKA and EKB are encoded only aTAC4 and
all four transcripts, respectively, and EKC and EKD are
encoded by aTAC4 and bTAC4, respectively [67].
EKA consists of 47 amino acids, while EKB is a 41 amino
acid truncated from of EKA with deletion of six amino acids.
EKA and EKB are N-terminal elongated forms of hHK-1, Thr—
Gly—Lys—Ala—Ser—Gln—Phe—Phe—Gly—Leu—Met—NH2. EKC
and EKD consist of 14 amino acids, and only two amino acids
at the N-terminal are inconsistent between these two pep-
tides. EKA and EKB share the C-terminal tachykinin signature
motif, while EKC and EKD possess a different C-terminal
sequence. An exception to their tachykinin signature motif
in EKC and EKD is a transition from the C-terminal methionine
to a leucine (Table 1) [28,67—69].
4.2. Distribution of hTAC4
To account for the extra level of complexity introduced by
the different splice variants, Page et al. [67] examined this
expression by designing specific PCR primers to overlap each
unique exon junction and showed that a and bTAC4 have very
restricted expression patterns. Indeed, aTAC4 was found only
in the adrenal gland and fetal liver, and bTAC4 was detected
in the heart, liver, bone marrow, prostate, adrenal gland and
testis. In contrast, g and dTAC4 were ubiquitously expressed
in human tissues with the most prolific expression in the
adrenal gland and placenta. There was a low expression of
TAC4 in the brain [28,67—69].
5. Pharmacological effects of endokinins
Intrathecal administration of EKA/B (the common C-terminal
decapeptide in EKA and EKB, Table 1) induced scratching
behavior and thermal hyperalgesia. Indeed, 103 M
(10 nmol/rat) of EKA/B produced scratching behavior and107—104 M (1 pmol—1 nmol/rat) induced thermal hyperal-
gesia, and their effects were attenuated by pretreatment
with NK1R antagonists [70]. Also, when EKA/B was intrathe-
cally administered twice with an interval of 15 min, marked
desensitization of scratching behavior was induced. Further-
more, the first administration of EKA/B or SP produced clear
cross-desensitization to SP or EKA/B [48]. On the other hand,
i.c.v. administration of EKA/B (10, 30, 100 pmol/mouse) and
EKA/B (1, 3, 12, 20 nmol/mouse) induced hyperalgesic and
analgesic effects, respectively [71,72]. These effects of EKA/
B were attenuated by treatment with SR140333B, an antago-
nist of NK1 receptor, indicating that the binding of EKA/B to
the NK1 receptor elicited these effects.
Intrathecal or i.c.v. administration of EKC/D (the common
C-terminal duodecapeptide in EKC and EKD, Table 1) elicited
a different effect from EKA/B. Intrathecal administration of
EKC/D alone did not evoke the scratching behavior and
thermal hyperalgesia that were induced by EKA/B adminis-
tration [70], although i.c.v. administration of EKC/D (1, 3, 12,
20 nmol/mouse) also dose-dependently induced analgesic
effects [71]. However, pretreatment with EKC/D prevented
the induction of scratching behavior and thermal hyperalge-
sia by intrathecal administration of EKA/B and SP, and c-Fos
expression in laminae I/II and V/VI of the spinal cord by
noxious thermal stimulation [49]. Furthermore, subcuta-
neous injection of EKC/D reduced an increase in paw volume
following carrageenan-induced inflammation and the
reduced withdrawal latency evoked by inflammation was
also attenuated by EKC/D administration [73]. Similarly,
the hyperalgesic effect induced by EKA/B was attenuated
by EKC/D [71].
A marked difference between EKC/D and SP or EKA/B is
the presence of leucine instead of methionine at the carboxyl
terminal of EKC/D (Table 1). Thus, to clarify the effect of
leucine at the carboxyl terminal of EKC/D, [Met12]-EKC/D
(Table 1), in which only leucine at the carboxyl terminal of
EKC/D was replaced with methionine, was intrathecally
administered, and the effect of pretreatment with this pep-
tide was evaluated. This peptide did not exhibit an inhibitory
effect on SP-induced scratching behavior or thermal hyper-
algesia, but conversely caused thermal hyperalgesia [49]. In
addition, pretreatment with [Leu11]-SP and [Leu10]-EKA/B
(Table 1), in which methionine at the carboxyl terminal of SP
or EKA/B was replaced by leucine, attenuated SP-induced
scratching behavior and thermal hyperalgesia [74]. Based on
these findings, it seems likely that leucine at the carboxyl
terminal of EKC/D has a crucial role in eliciting inhibitory
effects.
There is a structural similarity between EKC/D and some
known SP-derived NK1 receptor antagonists such as Spantide I
[75] and Antagonist D [76], since they have leucine at the
carboxyl terminus of these peptides. In addition, Spantide I
and Antagonist D have a D-type amino acid, D-tryptophan (D-
Trp), at the seventh and ninth positions of SP. Since the
peptide bonds of Gln6—Phe7, Phe7—Phe8 and Gly9—Leu10
in SP are hydrolyzed by endopeptidase-24.11 [77], it is
reasonable that the replacement of Phe7 and Gly9 in SP by
D-Trp renders resistance to hydrolysis by this enzyme and
produces metabolically stable SP-derived antagonists; how-
ever, the pharmacological effect of EKC/D-derived peptides
with D-Trp was different from that of SP-derived peptides.
Indeed, the effect of pretreatment with these peptides on
32 T. Nishimori et al.SP-induced scratching and thermal hyperalgesia, formalin-
induced flinching and carrageenan-induced inflammation was
dependent on the number of D-Trp. Intrathecal administra-
tion of [D-Trp8]-EKC/D and [D-Trp10]-EKC/D (Table 1) showed a
markedly long inhibitory effect, at least 14 h, whereas the
antagonistic effects of [D-Trp8,10]-EKC/D (Table 1) and EKC/D
without D-Trp disappeared after 1 h. Thus, these results
indicate that the effective duration of EKC/D-derived pep-
tides is dependent on the number of D-Trp in the carboxyl-
terminal region, and the less numerous the D-Trp, the more
marked the antagonistic effect [78].
Perspective
One subject that remains to be resolved is whether the HK-1-
preferred receptor is identical to the NK1 receptor. Treat-
ment with NK1 receptor antagonists attenuated behavioral
responses induced by HK-1 as well as SP, indicating that HK-1
and SP elicit the effect through the NK1 receptor. On the
other hand, pretreatment with EKC/D inhibited SP-induced
scratching behavior while there was little effect on HK-1-
induced scratching, indicating that EKC/D is a specific
antagonist of the NK1 receptor, but not the HK-1-preferred
receptor. In addition, there was a difference in a mode of
induction of cross-desensitization and thermal hyperalgesia
between r/mHK-1 and SP and in kinases involved in the
induction of desensitization by HK-1 and SP. Taken together,
a series of evidence suggests that the NK1 receptor may be
different from the HK-1-preferred receptor. Discovery of
specific antagonists against the HK-1-preferred receptor
and identification of the HK-1-preferred receptor gene will
provide a clue to clarify these unsolved issues.
Information on the distribution of TAC4 mRNA has been
accumulated for various tissues, and the expression of TAC4
mRNA is evident in both peripheral tissues and the nervous
system. The peripheral tissue and brain consist of various cell
types in which each cell has specific functions; however,
there is no information about the expression of TAC4 mRNA
in each cell, since data on the expression of TAC4 mRNA are
derived from blotting analyses. Development of a specific
antibody against HK-1 is essential for determining the expres-
sion of HK-1 by immunohistochemistry in each cell, and
application of in situ hybridization can clarify the localization
of each cell expressing TAC4 mRNA in each tissue or the
central nervous system. These data are useful for elucidating
the function of HK-1 in each cell of various tissues.
Physiological functions of HK-1 in the spinal level or
peripheral tissue remain to be elucidated, although the
abundant expression of TAC4 mRNA in peripheral tissues
and induction of scratching behavior following intrathecal
administration of HK-1 have been identified. Scratching is a
pain-related behavior since scratching behavior is induced by
SP, which is known as a neurotransmitter in pain processing;
however, the itch sensation also induces scratching behavior
and pain induces wiping behavior [79]. Thus, analysis of
behavior responses, such as scratching and wiping, after
administration of HK-1 into peripheral tissues may be useful
for clarifying the role of HK-1 in peripheral tissues.
Finally, most accumulated data are derived from the
spinal or supraspinal level whereas there is little data on
the function of HK-1 or endokinins in the trigeminal system.
Thus, it is interesting to examine the role of HK-1 in theorofacial region while comparing with the effect of HK-1 in
peripheral tissue at the spinal level.
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